undamentalytics Newsletter
Sign in

Lyell Immunopharma, Inc. revenue

Lyell Immunopharma, Inc.'s revenue was $36,000 in fiscal 2025, down 41.0% on the year before. Since fiscal 2019 ($657,000) it has grown at a compound -38.4% a year. Over the last twelve months it was $27,000.

Revenue history

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Revenue1811850000
Growth on the year before—+>999%+37.3%+695.1%−99.8%−53.1%−41.0%—

Revenue as reported in the company's 10-K and 10-Q filings (for banks, net interest income plus non-interest income). Growth is left blank when the earlier figure was zero or negative.

Revenue against peers

Biotechnology: the closest covered companies by revenue. Last twelve months.

CompanyRevenueGrowth3-year growth a year
Lyell Immunopharma, Inc. $27,000 -55.0% -91.8%
AIM Immunotech Inc. $95,000 -21.5% -17.3%
Ibio, Inc. $100,000 -75.0% -62.4%
Lisata Therapeutics, Inc. $100,000 -90.7% —
Celldex Therapeutics, Inc. $158,000 -97.3% -63.5%
Clene Inc. $197,000 -31.1% -36.9%

Compare with peers

Head to head: AIM vs LYELIBIO vs LYELLSTA vs LYEL

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Lyell Immunopharma, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Lyell Immunopharma, Inc.